Literature DB >> 2111059

Human monoclonal anti-D with reactivity against category DVI cells used in blood grouping and determination of the incidence of the category DVI phenotype in the DU population.

K A Leader1, B M Kumpel, G D Poole, J T Kirkwood, A H Merry, B A Bradley.   

Abstract

B-lymphoblastoid cell lines transformed by Epstein-Barr virus were produced from cells obtained from a hyperimmunised donor with serum anti-D activity against category DVI red cells and enriched for this activity by rosetting with category DVI red cells. Three clones produced IgG1 anti-D and had stable cell growth and continuous secretion of antibody in prolonged culture. The monoclonal antibodies reacted with category DVI red cells, when assessed manually and in an automated blood grouping system, and are useful blood grouping reagents for the detection of the category DVI phenotype. Using a radiometric technique, the number of antibody molecules bound to category DVI red cells from 5 individuals was estimated to range from 2,800 to 11,200 per cell. Five percent of blood donors classed as Du in the south western region were found to have the category DVI phenotype.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2111059     DOI: 10.1111/j.1423-0410.1990.tb02071.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

Review 1.  Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype.

Authors:  S Gerald Sandler; Leonard N Chen; Willy A Flegel
Journal:  Br J Haematol       Date:  2017-05-16       Impact factor: 6.998

2.  Antibody responses to the blood group antigen D in SCID mice reconstituted with human blood mononuclear cells.

Authors:  K A Leader; L M Macht; F Steers; B M Kumpel; C J Elson
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

3.  Whole exon 5 and intron 5 replaced by RHCE in DVa(Hus).

Authors:  Chaopeng Shao; Wen Xiong; Wei Wang
Journal:  J Hum Genet       Date:  2004-01-09       Impact factor: 3.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.